Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 3/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 10/20 | 0.46 |
| ▸ | CTSS | P25774 | 6/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL474893 | 1.00 | HDAC4 (0.47) | HDAC4HDAC1HDAC6CTSKCTSS | |
| SCHEMBL30788769 | 1.00 | HDAC4 (0.47) | HDAC4HDAC1HDAC6CTSKCTSS | |
| SCHEMBL10311801 | 0.92 | HDAC4 (0.46) | HDAC4HDAC1HDAC6CTSKCTSS | |
| SCHEMBL28622702 | 0.92 | HDAC4 (0.46) | HDAC4HDAC1HDAC6CTSKCTSS | |
| SCHEMBL6446073 | 0.89 | CYP1A2 (0.58) | HDAC4HDAC1HDAC6CTSKCTSS | |
| SCHEMBL6446074 | 0.89 | CYP1A2 (0.58) | HDAC4HDAC1HDAC6CTSKCTSS | |
| SCHEMBL16001103 | 0.86 | HDAC4 (0.47) | HDAC4HDAC1HDAC6CTSKCTSS | |
| SCHEMBL2119739 | 0.86 | CTSK (0.49) | HDAC4HDAC1HDAC6CTSKCTSS | |
| SCHEMBL2119738 | 0.86 | CTSK (0.49) | HDAC4HDAC1HDAC6CTSKCTSS | |
| SCHEMBL5580323 | 0.86 | CTSK (0.49) | HDAC4HDAC1HDAC6CTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034094-A1 | COMPOSITIONS AND METHODS FOR INDUCING FERROPTOSIS | KOJIN THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| EP-4565228-A2 | COMPOSITIONS AND METHODS FOR INDUCING FERROPTOSIS | Kojin Therapeutics, Inc. (US) | 2025-06-11 | — | — | EP | disclosed |
| CN-119264224-A | Novel fluorine substituted vancomycin analogue and preparation method and application thereof | 中国科学院上海有机化学研究所 | 2025-01-07 | — | — | CN | disclosed |
| WO-2024030960-A2 | COMPOSITIONS AND METHODS FOR INDUCING FERROPTOSIS | Kojin Therapeutics, Inc. (US) | 2024-02-08 | — | — | WO | disclosed |
| US-20120093726-A1 | Radiolabeled Fluorine Derivatives of Methionine | CRC FOR BIOMEDICAL IMAGING DEVELOPMENT LTD. (AU) | 2012-04-19 | — | — | US | disclosed |
| EP-2411360-A1 | RADIOLABELED FLUORINE DERIVATIVES OF METHIONINE | CRC For Biomedical Imaging Development Ltd (AU) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010108210-A1 | RADIOLABELED FLUORINE DERIVATIVES OF METHIONINE | CRC FOR BIOMEDICAL IMAGING DEVELOPMENT LTD (AU) | 2010-09-30 | — | — | WO | disclosed |
| US-6620848-B2 | Antiarthritic agents, antihistamines, headaches | SMITHKLINE BEECHAM CORPORATION | 2003-09-16 | — | — | US | disclosed |
| US-6369272-B1 | ENZYME INHIBITORS OF AMIDINE ALKYL SULFIDE AMINOACIDS | GLAXOSMITHKLINE | 2002-04-09 | — | — | US | disclosed |
| US-20020010366-A1 | Nitric oxide synthase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-01-24 | — | — | US | disclosed |
| EP-0958277-B1 | NITRIC OXIDE SYNTHASE INHIBITORS | GLAXO GROUP LTD (GB) | 2001-11-21 | — | — | EP | disclosed |
| EP-0958277-A1 | NITRIC OXIDE SYNTHASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1999-11-24 | — | — | EP | disclosed |
| WO-1998030537-A1 | NITRIC OXIDE SYNTHASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1998-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120093726-A1 | Radiolabeled Fluorine Derivatives of Methionine | BHMT2, MGMT, AHCY | HDAC4 4240/4885HDAC1 3505/4885HDAC6 3794/4885 |
| US-20260034094-A1 | COMPOSITIONS AND METHODS FOR INDUCING FERROPTOSIS | AIFM2, GPX4, HMOX1 | HDAC4 1576/4885HDAC1 1323/4885HDAC6 1640/4885 |
| US-20020010366-A1 | Nitric oxide synthase inhibitors | NOS1, NOS2, NOS3 | HDAC4 3014/4885HDAC1 1268/4885HDAC6 2241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.